Filing Details

Accession Number:
0000899243-17-003646
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-10 20:10:56
Reporting Period:
2017-02-08
Filing Date:
2017-02-10
Accepted Time:
2017-02-10 20:10:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
906709 Nektar Therapeutics NKTR Pharmaceutical Preparations (2834) 943134940
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1206869 W Howard Robin C/O Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco CA 94158
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-02-08 87,500 $4.65 265,408 No 4 M Direct
Common Stock Disposition 2017-02-08 87,500 $13.04 177,908 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2017-02-08 87,500 $0.00 87,500 $4.65
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2013-02-23 2017-02-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 410 Indirect by spouse
Footnotes
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration.
  2. This transaction was executed in multiple trades at prices ranging from $12.71 to $13.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.